Spinocerebellar ataxia type 6

Spinocerebellar ataxia type 6 (SCA6) is a condition characterized by progressive problems with movement. People with this condition initially experience problems with coordination and balance (ataxia). Other early signs and symptoms of SCA6 include speech difficulties, involuntary eye movements (nystagmus), and double vision. Over time, individuals with SCA6 may develop loss of coordination in their arms, tremors, and uncontrolled muscle tensing (dystonia).

Signs and symptoms of SCA6 typically begin in a person's forties or fifties but can appear anytime from childhood to late adulthood. Most people with this disorder require wheelchair assistance by the time they are in their sixties.

Frequency

The worldwide prevalence of SCA6 is estimated to be less than 1 in 100,000 individuals.

Causes

Mutations in the \textit{CACNA1A} gene cause SCA6. The \textit{CACNA1A} gene provides instructions for making a protein that forms a part of some calcium channels. These channels transport positively charged calcium atoms (calcium ions) across cell membranes. The movement of these ions is critical for normal signaling between nerve cells (neurons) in the brain and other parts of the nervous system. The \textit{CACNA1A} gene provides instructions for making one part (the alpha-1 subunit) of a calcium channel called CaV2.1. CaV2.1 channels play an essential role in communication between neurons in the brain.

The \textit{CACNA1A} gene mutations that cause SCA6 involve a DNA segment known as a CAG trinucleotide repeat. This segment is made up of a series of three DNA building blocks (cytosine, adenine, and guanine) that appear multiple times in a row. Normally, the CAG segment is repeated 4 to 18 times within the gene. In people with SCA6, the CAG segment is repeated 20 to 33 times. People with 20 repeats tend to experience signs and symptoms of SCA6 beginning in late adulthood, while people with a larger number of repeats usually have signs and symptoms from mid-adulthood.

An increase in the length of the CAG segment leads to the production of an abnormally long version of the alpha-1 subunit. This version of the subunit alters the location and function of the CaV2.1 channels. Normally the alpha-1 subunit is located within the cell membrane; the abnormal subunit is found in the cell membrane as well as in the fluid inside cells (cytoplasm), where it clusters together and forms clumps (aggregates). The effect these aggregates have on cell functioning is unknown. The lack of normal calcium channels in the cell membrane impairs cell communication between neurons.
in the brain. Diminished cell communication leads to cell death. Cells within the cerebellum, which is the part of the brain that coordinates movement, are particularly sensitive to the accumulation of these aggregates. Over time, a loss of cells in the cerebellum causes the movement problems characteristic of SCA6.

Inheritance Pattern

This condition is inherited in an autosomal dominant pattern, which means one copy of the altered gene in each cell is sufficient to cause the disorder.

In most cases, an affected person has one parent with the condition.

As the altered CACNA1A gene is passed down from one generation to the next, the length of the CAG trinucleotide repeat often slightly increases. A larger number of repeats is usually associated with an earlier onset of signs and symptoms. This phenomenon is called anticipation.

Other Names for This Condition

- SCA6
- type 6 spinocerebellar ataxia

Diagnosis & Management

Genetic Testing Information

- What is genetic testing? /primer/testing/genetictesting

Research Studies from ClinicalTrials.gov

- ClinicalTrials.gov https://clinicaltrials.gov/ct2/results?cond=%22spinocerebellar+ataxia+type+6%22+OR+%22Spinocerebellar+Ataxias%22

Other Diagnosis and Management Resources


Additional Information & Resources

Health Information from MedlinePlus

• Health Topic: Cerebellar Disorders
  https://medlineplus.gov/cerebellardisorders.html

• Health Topic: Movement Disorders
  https://medlineplus.gov/movementdisorders.html

Genetic and Rare Diseases Information Center
• Spinocerebellar ataxia type 6
  https://rarediseases.info.nih.gov/diseases/10351/spinocerebellar-ataxia-type-6

Additional NIH Resources
• National Institute of Neurological Disorders and Stroke: Ataxias and Cerebellar or Spinocerebellar Degeneration Information Page
  https://www.ninds.nih.gov/Disorders/All-Disorders/Ataxias-and-Cerebellar-or-Spinocerebellar-Degeneration-Information-Page

Educational Resources
• Boston Children's Hospital: Dysphagia
  http://www.childrenshospital.org/conditions-and-treatments/conditions/d/dysphagia

• Johns Hopkins Medicine Department of Neurology and Neurosurgery: What is Ataxia?
  https://www.hopkinsmedicine.org/neurology_neurosurgery/centers_clinics/ataxia/conditions/

• Merck Manual Home Edition for Patients and Caregivers: Coordination Disorders

• Orphanet: Spinocerebellar ataxia type 6
  https://www.orpha.net/consor/cgi-bin/OC_Exp.php?Lng=EN&Expert=98758

• Stanford University: HOPES
  https://hopes.stanford.edu/trinucleotide-repeat-disorders/#sca6-spinocerebellar-ataxia-type-6

• Washington University, St. Louis: Neuromuscular Disease Center
  https://neuromuscular.wustl.edu/ataxia/domatax.html#6
Patient Support and Advocacy Resources

- Family Caregiver Alliance
  https://www.caregiver.org/
- National Ataxia Foundation
  https://ataxia.org/
- National Organization for Rare Disorders (NORD): Autosomal Dominant Hereditary Ataxia
  https://rarediseases.org/rare-diseases/autosomal-dominant-hereditary-ataxia/

Clinical Information from GeneReviews

- Spinocerebellar Ataxia Type 6
  https://www.ncbi.nlm.nih.gov/books/NBK1140

Scientific Articles on PubMed

- PubMed
  https://www.ncbi.nlm.nih.gov/pubmed?term=%28Spinocerebellar+Ataxias%5BMAJR%5D%29+AND+%28%28Spinocerebellar+ataxia+type+6%5BTIAB%5D%29+OR+%28sca6%5BTIAB%5D%29+AND+english%5Bla%5D+AND+human%5Bmh%5D+AND+%22last+1440+days%22+AND+human%5Bdp%5D

Catalog of Genes and Diseases from OMIM

- SPINOCEREBELLAR ATAXIA 6
  http://omim.org/entry/183086

Sources for This Summary

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/20301319
  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/20043227
  Free article on PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2841749/
  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/17395139
  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/20948794
  Free article on PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2948357/